Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of anidulafungin in children and adolescents with invasive candidiasis, including candidemia
2008-004150-32Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2008
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anidulafungin in invasive candidiasis and candidemia, sponsored by Pfizer. Primary endpoints: Safety and tolerability of anidulafungin and Pharmacokinetics of anidulafungin. Started Sep 2008; status: completed.
02
Drugs
anidulafungin
03
Conditions
invasive candidiasiscandidemia
Beyond the preview
Go deeper on 2008-004150-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004150-32.